No products in the cart.
Pre-made Lulizumab benchmark antibody ( Single Domain Variable Fragment;L, anti-CD28 therapeutic antibody, Anti-Tp44 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-326
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lulizumab pegol (INN; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases. This drug was developed by Bristol-Myers Squibb.
| Products Name (INN Index) | Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody |
|---|---|
| INN Name | Lulizumab |
| Target | CD28 |
| Format | Single Domain Variable Fragment;L |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Bristol-Myers Squibb |
| Conditions Approved | NA |
| Conditions Active | Sjogren's syndrome,Systemic lupus erythematosus,Renal transplant rejection |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD28 |
| Package |
Previous slide
Next slide
